Integrative Genomic Profiling of Human Prostate Cancer

Barry S. Taylor; Nikolaus Schultz; Haley Hieronymus; Anuradha Gopalan; Yonghong Xiao; Brett S. Carver; Vivek K. Arora; Poorvi Kaushik; Ethan Cerami; Boris Reva; Yevgeniy Antipin; Nicholas Mitsiades; Thomas Landers; Igor Dolgalev; John E. Major; Manda Wilson; Nicholas D. Socci; Alex E. Lash; Adriana Heguy; James A. Eastham; Howard I. Scher; Victor E. Reuter; Peter T. Scardino; Chris Sander; Charles L. Sawyers; William L. Gerald

doi:10.1016/j.ccr.2010.05.026

Integrative Genomic Profiling of Human Prostate Cancer

Barry S. Taylor
, Nikolaus Schultz
, Haley Hieronymus
, Anuradha Gopalan
, Yonghong Xiao
, Brett S. Carver
, Vivek K. Arora
, Poorvi Kaushik
, Ethan Cerami
, Boris Reva
, Yevgeniy Antipin
, Nicholas Mitsiades
, Thomas Landers
, Igor Dolgalev
, John E. Major
, Manda Wilson
, Nicholas D. Socci
, Alex E. Lash
, Adriana Heguy
, James A. Eastham

Howard I. Scher, Victor E. Reuter, Peter T. Scardino, Chris Sander, Charles L. Sawyers, William L. Gerald

Research output: Contribution to journal › Article › peer-review

3198 Scopus citations

Abstract

Annotation of prostate cancer genomes provides a foundation for discoveries that can impact disease understanding and treatment. Concordant assessment of DNA copy number, mRNA expression, and focused exon resequencing in 218 prostate cancer tumors identified the nuclear receptor coactivator NCOA2 as an oncogene in ∼11% of tumors. Additionally, the androgen-driven TMPRSS2-ERG fusion was associated with a previously unrecognized, prostate-specific deletion at chromosome 3p14 that implicates FOXP1, RYBP, and SHQ1 as potential cooperative tumor suppressors. DNA copy-number data from primary tumors revealed that copy-number alterations robustly define clusters of low- and high-risk disease beyond that achieved by Gleason score. The genomic and clinical outcome data from these patients are now made available as a public resource.

Original language	English
Pages (from-to)	11-22
Number of pages	12
Journal	Cancer Cell
Volume	18
Issue number	1
DOIs	https://doi.org/10.1016/j.ccr.2010.05.026
State	Published - Jul 2010
Externally published	Yes

Access to Document

10.1016/j.ccr.2010.05.026

Cite this

Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., Antipin, Y., Mitsiades, N., Landers, T., Dolgalev, I., Major, J. E., Wilson, M., Socci, N. D., Lash, A. E., Heguy, A., ... Gerald, W. L. (2010). Integrative Genomic Profiling of Human Prostate Cancer. Cancer Cell, 18(1), 11-22. https://doi.org/10.1016/j.ccr.2010.05.026

@article{59e088f336e2423bacd4012bfac1cce2,

title = "Integrative Genomic Profiling of Human Prostate Cancer",

abstract = "Annotation of prostate cancer genomes provides a foundation for discoveries that can impact disease understanding and treatment. Concordant assessment of DNA copy number, mRNA expression, and focused exon resequencing in 218 prostate cancer tumors identified the nuclear receptor coactivator NCOA2 as an oncogene in ∼11\% of tumors. Additionally, the androgen-driven TMPRSS2-ERG fusion was associated with a previously unrecognized, prostate-specific deletion at chromosome 3p14 that implicates FOXP1, RYBP, and SHQ1 as potential cooperative tumor suppressors. DNA copy-number data from primary tumors revealed that copy-number alterations robustly define clusters of low- and high-risk disease beyond that achieved by Gleason score. The genomic and clinical outcome data from these patients are now made available as a public resource.",

author = "Taylor, \{Barry S.\} and Nikolaus Schultz and Haley Hieronymus and Anuradha Gopalan and Yonghong Xiao and Carver, \{Brett S.\} and Arora, \{Vivek K.\} and Poorvi Kaushik and Ethan Cerami and Boris Reva and Yevgeniy Antipin and Nicholas Mitsiades and Thomas Landers and Igor Dolgalev and Major, \{John E.\} and Manda Wilson and Socci, \{Nicholas D.\} and Lash, \{Alex E.\} and Adriana Heguy and Eastham, \{James A.\} and Scher, \{Howard I.\} and Reuter, \{Victor E.\} and Scardino, \{Peter T.\} and Chris Sander and Sawyers, \{Charles L.\} and Gerald, \{William L.\}",

note = "Funding Information: This work is dedicated to the memory of our colleague and friend William Gerald who initiated this project. We are grateful for the technical assistance and support of A. Viale (MSKCC Genomics Core), K. Huberman, S. Thomas, O. Aminova (Beene Translational Oncology Core), A. Olshen, J. Satagopan (Epidemiology and Biostatistics), L. Vargas, L. Chen (Pathology), and A. Gabow (Bioinformatics Core). This work was supported in part by the MSKCC Prostate SPORE CA092629 and by the David H. Koch Foundation. C.L.S. is an Investigator of the Howard Hughes Medical Institute. ",

year = "2010",

month = jul,

doi = "10.1016/j.ccr.2010.05.026",

language = "English",

volume = "18",

pages = "11--22",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "1",

}

Taylor, BS, Schultz, N, Hieronymus, H, Gopalan, A, Xiao, Y, Carver, BS, Arora, VK, Kaushik, P, Cerami, E, Reva, B, Antipin, Y, Mitsiades, N, Landers, T, Dolgalev, I, Major, JE, Wilson, M, Socci, ND, Lash, AE, Heguy, A, Eastham, JA, Scher, HI, Reuter, VE, Scardino, PT, Sander, C, Sawyers, CL & Gerald, WL 2010, 'Integrative Genomic Profiling of Human Prostate Cancer', Cancer Cell, vol. 18, no. 1, pp. 11-22. https://doi.org/10.1016/j.ccr.2010.05.026

TY - JOUR

T1 - Integrative Genomic Profiling of Human Prostate Cancer

AU - Taylor, Barry S.

AU - Schultz, Nikolaus

AU - Hieronymus, Haley

AU - Gopalan, Anuradha

AU - Xiao, Yonghong

AU - Carver, Brett S.

AU - Arora, Vivek K.

AU - Kaushik, Poorvi

AU - Cerami, Ethan

AU - Reva, Boris

AU - Antipin, Yevgeniy

AU - Mitsiades, Nicholas

AU - Landers, Thomas

AU - Dolgalev, Igor

AU - Major, John E.

AU - Wilson, Manda

AU - Socci, Nicholas D.

AU - Lash, Alex E.

AU - Heguy, Adriana

AU - Eastham, James A.

AU - Scher, Howard I.

AU - Reuter, Victor E.

AU - Scardino, Peter T.

AU - Sander, Chris

AU - Sawyers, Charles L.

AU - Gerald, William L.

N1 - Funding Information: This work is dedicated to the memory of our colleague and friend William Gerald who initiated this project. We are grateful for the technical assistance and support of A. Viale (MSKCC Genomics Core), K. Huberman, S. Thomas, O. Aminova (Beene Translational Oncology Core), A. Olshen, J. Satagopan (Epidemiology and Biostatistics), L. Vargas, L. Chen (Pathology), and A. Gabow (Bioinformatics Core). This work was supported in part by the MSKCC Prostate SPORE CA092629 and by the David H. Koch Foundation. C.L.S. is an Investigator of the Howard Hughes Medical Institute.

PY - 2010/7

Y1 - 2010/7

N2 - Annotation of prostate cancer genomes provides a foundation for discoveries that can impact disease understanding and treatment. Concordant assessment of DNA copy number, mRNA expression, and focused exon resequencing in 218 prostate cancer tumors identified the nuclear receptor coactivator NCOA2 as an oncogene in ∼11% of tumors. Additionally, the androgen-driven TMPRSS2-ERG fusion was associated with a previously unrecognized, prostate-specific deletion at chromosome 3p14 that implicates FOXP1, RYBP, and SHQ1 as potential cooperative tumor suppressors. DNA copy-number data from primary tumors revealed that copy-number alterations robustly define clusters of low- and high-risk disease beyond that achieved by Gleason score. The genomic and clinical outcome data from these patients are now made available as a public resource.

AB - Annotation of prostate cancer genomes provides a foundation for discoveries that can impact disease understanding and treatment. Concordant assessment of DNA copy number, mRNA expression, and focused exon resequencing in 218 prostate cancer tumors identified the nuclear receptor coactivator NCOA2 as an oncogene in ∼11% of tumors. Additionally, the androgen-driven TMPRSS2-ERG fusion was associated with a previously unrecognized, prostate-specific deletion at chromosome 3p14 that implicates FOXP1, RYBP, and SHQ1 as potential cooperative tumor suppressors. DNA copy-number data from primary tumors revealed that copy-number alterations robustly define clusters of low- and high-risk disease beyond that achieved by Gleason score. The genomic and clinical outcome data from these patients are now made available as a public resource.

UR - https://www.scopus.com/pages/publications/77954255681

U2 - 10.1016/j.ccr.2010.05.026

DO - 10.1016/j.ccr.2010.05.026

M3 - Article

C2 - 20579941

AN - SCOPUS:77954255681

SN - 1535-6108

VL - 18

SP - 11

EP - 22

JO - Cancer Cell

JF - Cancer Cell

IS - 1

ER -

Integrative Genomic Profiling of Human Prostate Cancer

Abstract

Access to Document

Fingerprint

Cite this